亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

医学 安慰剂 特发性肺纤维化 耐受性 CTGF公司 内科学 人口 肺活量 外科 不利影响 病理 肺 生长因子 扩散能力 替代医学 受体 环境卫生 肺功能
作者
Luca Richeldi,Evans R. Fernández Pérez,Ulrich Costabel,Carlo Albera,David J. Lederer,Kevin R. Flaherty,Neil A. Ettinger,Rafael L. Perez,Mary Beth Scholand,Jonathan Gerald Goldin,Kin-Hung Peony Yu,Thomas B. Neff,Seth Porter,Ming Zhong,Eduard Gorina,Elias Kouchakji,Ganesh Raghu
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (1): 25-33 被引量:300
标识
DOI:10.1016/s2213-2600(19)30262-0
摘要

Summary

Background

Connective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role in the process of fibrosis. This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis. The aim was to establish whether pamrevlumab could slow, stop, or reverse progression of idiopathic pulmonary fibrosis.

Methods

The phase 2, randomised, double-blind, placebo-controlled PRAISE trial was done at 39 medical centres in seven countries (Australia, Bulgaria, Canada, India, New Zealand, South Africa, and the USA). Patients with idiopathic pulmonary fibrosis and percentage of predicted forced vital capacity (FVC) of 55% or greater were enrolled and randomly assigned (1:1) by use of interactive responsive technology to intravenous infusion of pamrevlumab 30 mg/kg or placebo every 3 weeks over 48 weeks (16 infusions). The primary efficacy outcome was change from baseline in percentage of predicted FVC at week 48. Disease progression (defined as a decline from baseline in percentage of predicted FVC of ≥10%, or death) at week 48 was a key secondary efficacy outcome. All patients in the pamrevlumab group received at least one dose of the study drug and were analysed for safety. Two patients in the placebo group were excluded from the intention-to-treat population for the efficacy analyses because of enrolment error. This trial is registered with ClinicalTrials.gov, NCT01890265.

Findings

Between Aug 17, 2013, and July 21, 2017, 103 patients were randomly assigned (50 to pamrevlumab and 53 to placebo). Pamrevlumab reduced the decline in percentage of predicted FVC by 60·3% at week 48 (mean change from baseline −2·9% with pamrevlumab vs −7·2% with placebo; between-group difference 4·3% [95% CI 0·4–8·3]; p=0·033). The proportion of patients with disease progression was lower in the pamrevlumab group than in the placebo group at week 48 (10·0% vs 31·4%; p=0·013). Pamrevlumab was well tolerated, with a safety profile similar to that of placebo. Treatment-emergent serious adverse events were observed in 12 (24%) patients in the pamrevlumab group and eight (15%) in the placebo group, with three patients on pamrevlumab and seven on placebo discontinuing treatment. Of the three (6%) deaths in the pamrevlumab group and six (11%) in the placebo group, none was considered treatment related.

Interpretation

Pamrevlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated. Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis.

Funding

FibroGen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
俭朴紫文完成签到,获得积分10
3秒前
4秒前
良久完成签到 ,获得积分10
4秒前
xl完成签到,获得积分10
7秒前
zrl完成签到,获得积分20
8秒前
9秒前
神勇的筝完成签到,获得积分10
10秒前
王占雪完成签到 ,获得积分10
10秒前
11秒前
王老裂完成签到,获得积分10
12秒前
h11的应助被纯情的阁采纳,获得10
13秒前
h11的应助被纯情的阁采纳,获得10
13秒前
h11的应助被纯情的阁采纳,获得10
14秒前
h11的应助被纯情的阁采纳,获得10
14秒前
h11的应助被纯情的阁采纳,获得10
14秒前
h11的应助被纯情的阁采纳,获得10
14秒前
Monster发布了新的文献求助10
14秒前
年轻牛排完成签到 ,获得积分10
14秒前
奔跑的应助被纯情的阁采纳,获得10
14秒前
h11的应助被纯情的阁采纳,获得10
15秒前
sunflower发布了新的文献求助10
15秒前
19秒前
迷路万天完成签到,获得积分10
22秒前
Jasper的应助被研猫采纳,获得10
23秒前
24秒前
25秒前
wshwx完成签到,获得积分10
25秒前
26秒前
26秒前
张日国完成签到,获得积分10
26秒前
传奇3的应助被染8采纳,获得10
27秒前
SCI完成签到,获得积分10
29秒前
30秒前
强健的梦秋完成签到,获得积分10
31秒前
33秒前
老实弼完成签到,获得积分10
33秒前
SCI发布了新的文献求助10
33秒前
33秒前
35秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158582
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719049
捐赠科研通 7748110
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551881
邀请新用户注册赠送积分活动 2471262